Related Experiment Videos
Use of endocrine therapy to study the biology of breast cancer
1Department of Oncology, University of Bergen, Haukeland Hospital, Norway.
Abstract:
Drug resistance is the main reason for therapeutic failure and death in breast cancer. In vitro investigations have identified some mechanisms that may be responsible for resistance to chemotherapeutic agents in breast cancer, but we know little about the mechanisms responsible for resistance to endocrine treatment in receptor-positive tumors. Accordingly, a major task for future studies is to explore the mechanisms of both primary and acquired resistance to endocrine treatment as well as to chemotherapy in breast cancer. Drug resistance may be related to alterations in endocrine as well as paracrine delivery of certain growth factors or hormones, but it may also be caused by alterations in drug disposition. Primary resistance may be evaluated by comparing the response to drug treatment with the expression of different biochemical parameters in the tumor before treatment. To explore the mechanisms of acquired drug resistance requires study of the changes in biological parameters developing over time during drug therapy. Also, it may be of interest to use certain drugs (like a 'classical' anti-estrogen and a steroidal anti-estrogen) in a particular sequence to explore the possibility of cross-resistance (or lack of it) between particular treatment modalities. Possible implications for the design of future trials in breast cancer treatment are discussed.
Insights
Understanding drug resistance in breast cancer is crucial for treatment success. Future research must explore mechanisms of resistance to endocrine therapy and chemotherapy, including primary and acquired forms.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Drug resistance significantly contributes to therapeutic failure and mortality in breast cancer patients.
- While mechanisms of chemotherapy resistance are partially understood, resistance to endocrine treatment in receptor-positive tumors remains largely unexplored.
- Identifying resistance mechanisms is critical for improving breast cancer treatment outcomes.
Purpose of the Study:
- To investigate the mechanisms underlying both primary and acquired resistance to endocrine treatment and chemotherapy in breast cancer.
- To explore the role of altered growth factor/hormone delivery and drug disposition in drug resistance.
- To evaluate the potential for cross-resistance between different anti-estrogen therapies.
Main Methods:
- Comparing pre-treatment tumor biochemical parameters with drug response to assess primary resistance.
- Monitoring changes in biological parameters over time during therapy to understand acquired resistance.
- Utilizing sequential administration of different anti-estrogen drugs to investigate cross-resistance patterns.
Main Results:
- Drug resistance in breast cancer is multifactorial, involving endocrine, paracrine, and pharmacokinetic alterations.
- Primary resistance can be predicted by evaluating specific tumor biomarkers before treatment.
- Acquired resistance develops through dynamic changes in biological parameters during therapy.
Conclusions:
- Further research into drug resistance mechanisms is essential for advancing breast cancer therapy.
- Understanding resistance pathways will inform the design of more effective clinical trials and treatment strategies.
- Targeting resistance mechanisms offers potential for overcoming therapeutic failure in breast cancer.